RESUMEN
Equid alphaherpesviruses 1 (EHV-1) and 4 (EHV-4) are closely related and both endemic in horses worldwide. Both viruses replicate in the upper respiratory tract, but EHV-1 may additionally lead to abortion and equine herpesvirus myeloencephalopathy (EHM). We focused on antibody responses in horses against the receptor-binding glycoprotein D of EHV-1 (gD1), which shares a 77% amino acid identity with its counterpart in EHV-4 (gD4). Both antigens give rise to cross-reacting antibodies, including neutralizing antibodies. However, immunity against EHV-4 is not considered protective against EHM. While a diagnostic ELISA to discriminate between EHV-1 and EHV-4 infections is available based on type-specific fragments of glycoprotein G (gG1 and gG4, respectively), the type-specific antibody reaction against gD1 has not yet been sufficiently addressed. Starting from the N-terminus of gD1, we developed luciferase immunoprecipitation system (LIPS) assays, using gD1-fragments of increasing size as antigens, i.e. gD1_83 (comprising the first 83 amino acids), gD1_160, gD1_180, and gD1_402 (the full-length molecule). These assays were then used to analyse panels of horse sera from Switzerland (n = 60) and Iceland (n = 50), the latter of which is considered EHV-1 free. We detected only one true negative horse serum from Iceland, whereas all other sera in both panels were seropositive for both gG4 (ELISA) and gD1 (LIPS against gD1_402). In contrast, seropositivity against gG1 was rather rare (35% Swiss sera; 14% Icelandic sera). Therefore, a high percentage of antibodies against gD1 could be attributed to cross-reaction and due to EHV-4 infections. In contrast, the gD1_83 fragment was able to identify sera with type-specific antibodies against gD1. Interestingly, those sera stemmed almost exclusively from vaccinated horses. Although it is uncertain that the N-terminal epitopes of gD1 addressed in this communication are linked to better protection, we suggest that in future vaccine developments, type-common antigens should be avoided, while a broad range of type-specific antigens should be favored.
Asunto(s)
Anticuerpos Antivirales , Herpesvirus Équido 1 , Enfermedades de los Caballos , Proteínas del Envoltorio Viral , Animales , Caballos/inmunología , Herpesvirus Équido 1/inmunología , Anticuerpos Antivirales/inmunología , Anticuerpos Antivirales/sangre , Proteínas del Envoltorio Viral/inmunología , Enfermedades de los Caballos/virología , Enfermedades de los Caballos/inmunología , Enfermedades de los Caballos/prevención & control , Herpesvirus Équido 4/inmunología , Infecciones por Herpesviridae/veterinaria , Infecciones por Herpesviridae/inmunología , Infecciones por Herpesviridae/virología , Reacciones Cruzadas/inmunología , Ensayo de Inmunoadsorción Enzimática , Anticuerpos Neutralizantes/inmunología , Anticuerpos Neutralizantes/sangre , Dominios Proteicos/inmunologíaRESUMEN
Hendra virus (HeV) is lethal to horses and a zoonotic threat to humans in Australia, causing severe neurological and/or respiratory disease with high mortality. An equine vaccine has been available since 2012. Foals acquire antibodies from their dams by ingesting colostrum after parturition, therefore it is assumed that foals of mares vaccinated against HeV will have passive HeV antibodies circulating during the first several months of life until they are actively vaccinated. However, no studies have yet examined passive or active immunity against HeV in foals. Here, we investigated anti-HeV antibody levels in vaccinated mares and their foals. Testing for HeV neutralising antibodies is cumbersome due to the requirement for Biosafety level 4 (BSL-4) containment to conduct virus neutralisation tests (VNT). For this study, a subset of samples was tested for HeV G-specific antibodies by both an authentic VNT with infectious HeV and a microsphere-based immunoassay (MIA), revealing a strong correlation. An indicative neutralising level was then applied to the results of a larger sample set tested using the MIA. Mares had high levels of HeV-specific neutralising antibodies at the time of parturition. Foals acquired high levels of maternal antibodies which then waned to below predictive protective levels in most foals by 6 months old when vaccination commenced. Foals showed a suboptimal response to vaccination, suggesting maternal antibodies may interfere with active vaccination. The correlation analysis between the authentic HeV VNT and HeV MIA will enable further high throughput serological studies to inform optimal vaccination protocols for both broodmares and foals.
Asunto(s)
Anticuerpos Neutralizantes , Anticuerpos Antivirales , Virus Hendra , Infecciones por Henipavirus , Enfermedades de los Caballos , Vacunación , Vacunas Virales , Animales , Caballos , Virus Hendra/inmunología , Enfermedades de los Caballos/prevención & control , Enfermedades de los Caballos/virología , Enfermedades de los Caballos/inmunología , Anticuerpos Antivirales/sangre , Infecciones por Henipavirus/prevención & control , Infecciones por Henipavirus/veterinaria , Infecciones por Henipavirus/inmunología , Infecciones por Henipavirus/virología , Femenino , Vacunación/veterinaria , Vacunas Virales/inmunología , Vacunas Virales/administración & dosificación , Anticuerpos Neutralizantes/sangre , Inmunidad Materno-Adquirida , Animales Recién Nacidos/inmunología , Embarazo , Pruebas de Neutralización/veterinaria , Australia , Calostro/inmunologíaRESUMEN
Introduction: Equine asthma (EA) is a common lower airway disease in horses, but whether its pathogenesis is allergic is ambiguous. Extrinsic stimuli like hay dust induce acute exacerbation of clinical signs and sustained local neutrophilic inflammation in susceptible horses. Aspergillus fumigatus is an EA stimulus, but it is unclear if it merely acts as an IgE-provoking allergen. We aimed to comprehensively analyze immunoglobulin (Ig) isotypes in EA, elucidating their binding to different A. fumigatus antigens, and their quantities systemically in serum and locally in bronchoalveolar lavage fluid (BALF). Methods: Serum and BALF from healthy horses (HE, n = 18) and horses with mild-moderate asthma (MEA, n = 20) or severe asthma (SEA, n = 24) were compared. Ig isotype (IgG1, IgG3/5, IgG4/7, IgG6, IgA, and IgE) binding to nine antigens (A. fumigatus lysate, and recombinant Asp f 1, Asp f 7, Asp f 8, dipeptidyl-peptidase 5, class II aldolase/adducin domain protein, glucoamylase, beta-hexosaminidase, and peptide hydrolase) was compared by enzyme-linked immunosorbent assays. Total Ig isotype contents were determined by bead-based assays. Results: MEA and SEA differed from HE but hardly from each other. Compared to HE, asthmatic horses showed increased anti-A. fumigatus binding of IgG (BALF and serum) and IgA (BALF). Serum and BALF IgE binding and total IgE contents were similar between HE and EA. Single antigens, as well as A. fumigatus lysate, yielded similar Ig binding patterns. Serum and BALF IgG1 binding to all antigens was increased in SEA and to several antigens in MEA. Serum IgG4/7 binding to two antigens was increased in SEA. BALF IgA binding to all antigens was increased in SEA and MEA. Total BALF IgG1 and IgG4/7 contents were increased in SEA, and serum IgG4/7 content was increased in MEA compared to HE. Yet, total isotype contents differentiated EA and HE less clearly than antigen-binding Ig. Discussion: A. fumigatus immunogenicity was confirmed without identification of single dominant antigens here. A. fumigatus provoked elevated BALF IgG1 and IgA binding, and these isotypes appear relevant for neutrophilic EA, which does not support allergy. BALF Ig isotype differentiation beyond IgE is crucial for a comprehensive analysis of immune responses to fungi in EA pathogenesis.
Asunto(s)
Antígenos Fúngicos , Aspergillus fumigatus , Asma , Líquido del Lavado Bronquioalveolar , Enfermedades de los Caballos , Inmunoglobulina A , Inmunoglobulina G , Animales , Caballos/inmunología , Aspergillus fumigatus/inmunología , Líquido del Lavado Bronquioalveolar/inmunología , Asma/inmunología , Asma/microbiología , Inmunoglobulina G/inmunología , Inmunoglobulina G/sangre , Inmunoglobulina A/inmunología , Inmunoglobulina A/sangre , Inmunoglobulina A/metabolismo , Enfermedades de los Caballos/inmunología , Enfermedades de los Caballos/microbiología , Antígenos Fúngicos/inmunología , Masculino , Neutrófilos/inmunología , Neutrófilos/metabolismo , Femenino , Inmunoglobulina E/inmunología , Inmunoglobulina E/sangre , Anticuerpos Antifúngicos/inmunología , Anticuerpos Antifúngicos/sangreRESUMEN
Background: Insect bite hypersensitivity (IBH) is the most frequent skin allergy of horses and is highly debilitating, especially in the chronic phase. IBH is caused by IgE-mediated hypersensitivity reactions to culicoides midge bites and an imbalanced immune response that reduces the welfare of affected horses. Objective: In the present study, we investigated the pathological mechanisms of IBH, aiming to understand the immune cell modulation in acute allergic skin lesions of IBH horses with the goal of finding possible biomarkers for a diagnostic approach to monitor treatment success. Methods: By qPCR, we quantified the gene expression of cytokines, chemokines, and immune receptors in skin punch biopsies of IBH with different severity levels and healthy horses simultaneously in tandem with the analysis of immune cell counts in the blood. Results: Our data show an increase in blood eosinophils, monocytes, and basophils with a concomitant, significant increase in associated cytokine, chemokine, and immune cell receptor mRNA expression levels in the lesional skin of IBH horses. Moreover, IL-5Ra, CCR5, IFN-γ, and IL-31Ra were strongly associated with IBH severity, while IL-31 and IL-33 were rather associated with a milder form of IBH. In addition, our data show a strong correlation of basophil cell count in blood with IL-31Ra, IL-5, IL-5Ra, IFN-γ, HRH2, HRH4, CCR3, CCR5, IL-12b, IL-10, IL-1ß, and CCL26 mRNA expression in skin punch biopsies of IBH horses. Conclusion: In summary, several cytokines and chemokines have been found to be associated with disease severity, hence contributing to IBH pathology. These molecules can be used as potential biomarkers to monitor the onset and progression of the disease or even to evaluate and monitor the efficacy of new therapeutic treatments for IBH skin allergy. To our knowledge, this is the first study that investigated immune cells together with a large set of genes related to their biological function, including correlation to disease severity, in a large cohort of healthy and IBH horses.
Asunto(s)
Quimiocinas , Citocinas , Enfermedades de los Caballos , Mordeduras y Picaduras de Insectos , Piel , Animales , Caballos , Mordeduras y Picaduras de Insectos/inmunología , Mordeduras y Picaduras de Insectos/veterinaria , Piel/inmunología , Piel/patología , Enfermedades de los Caballos/inmunología , Quimiocinas/genética , Hipersensibilidad/inmunología , Hipersensibilidad/veterinaria , Índice de Severidad de la Enfermedad , Ceratopogonidae/inmunología , Masculino , Femenino , BiomarcadoresRESUMEN
In this review, we explore how pseudotyped viruses (PVs) are being applied to the study of viruses affecting both humans and horses. For the purposes of this review, we define PVs as non-replicative viruses with the core of one virus and the surface protein(s) of another and encapsulating a reporter gene such as luciferase. These 'reporter' PVs enable receptor-mediated entry into host cells to be quantified, and thus can be applied to study the initial stages of viral replication. They can also be used to test antiviral activity of compounds and measure envelope protein-specific antibodies in neutralisation tests.
Asunto(s)
Enfermedades de los Caballos , Virosis , Caballos , Animales , Humanos , Virosis/inmunología , Virosis/virología , Virosis/veterinaria , Enfermedades de los Caballos/virología , Enfermedades de los Caballos/inmunología , Enfermedades de los Caballos/epidemiología , Virus/inmunología , Virus/genética , Virus/patogenicidad , Virus/clasificación , Replicación Viral , Internalización del Virus , Anticuerpos Antivirales/inmunologíaRESUMEN
Equid alphaherpesvirus 1 (EqAHV1) is a viral pathogen known to cause respiratory disease, neurologic syndromes, and abortion storms in horses. Currently, there are no vaccines that provide complete protection against EqAHV1. Marker vaccines and the differentiation of infected and vaccinated animals (DIVA) strategy are effective for preventing and controlling outbreaks but have not been used for the prevention of EqAHV1 infection. Glycoprotein 2 (gp2), located on the envelope of viruses (EqAHV1), exhibits high antigenicity and functions as a molecular marker for DIVA. In this study, a series of EqAHV1 mutants with deletion of gp2 along with other virulence genes (TK, UL24/TK, gI/gE) were engineered. The mutant viruses were studied in vitro and then in an in vivo experiment using Golden Syrian hamsters to assess the extent of viral attenuation and the immune response elicited by the mutant viruses in comparison to the wild-type (WT) virus. Compared with the WT strain, the YM2019 Δgp2, ΔTK/gp2, and ΔUL24/TK/gp2 strains exhibited reduced growth in RK-13 cells, while the ΔgI/gE/gp2 strain exhibited significantly impaired proliferation. The YM2019 Δgp2 strain induced clinical signs and mortality in hamsters. In contrast, the YM2019 ΔTK/gp2 and ΔUL24/TK/gp2 variants displayed diminished pathogenicity, causing no observable clinical signs or fatalities. Immunization with nasal vaccines containing YM2019 ΔTK/gp2 and ΔUL24/TK/gp2 elicited a robust immune response in hamsters. In particular, compared with the vaccine containing the ΔTK/gp2 strain, the vaccine containing the ΔUL24/TK/gp2 strain demonstrated enhanced immune protection upon challenge with the WT virus. Furthermore, an ELISA for gp2 was established and refined to accurately differentiate between infected and vaccinated animals. These results confirm that the ΔUL24/TK/gp2 strain is a safe and effective live attenuated vaccine candidate for controlling EqAHV1 infection.
Asunto(s)
Infecciones por Herpesviridae , Herpesvirus Équido 1 , Vacunas Atenuadas , Animales , Vacunas Atenuadas/inmunología , Infecciones por Herpesviridae/prevención & control , Infecciones por Herpesviridae/inmunología , Infecciones por Herpesviridae/virología , Infecciones por Herpesviridae/veterinaria , Herpesvirus Équido 1/inmunología , Herpesvirus Équido 1/genética , Caballos , Mesocricetus , Anticuerpos Antivirales/sangre , Anticuerpos Antivirales/inmunología , Proteínas del Envoltorio Viral/inmunología , Proteínas del Envoltorio Viral/genética , Cricetinae , Enfermedades de los Caballos/prevención & control , Enfermedades de los Caballos/inmunología , Enfermedades de los Caballos/virología , Vacunas Virales/inmunología , Vacunas Virales/genética , Línea Celular , MutaciónRESUMEN
Inflammatory myopathies or myositis encompass diseases characterized by the presence of inflammatory cellular infiltrates, mainly polymorphonuclear cells and/or lymphocytes, in muscle. This is in contrast to most forms of muscle disease characterized by myodegeneration that results in macrophage infiltration. Inflammatory myopathies could have infectious or noninfectious causes. Noninfectious causes consist of primary (genetic, autoimmune) or acquired immune-mediated disease. Focal, multifocal or diffuse, acute or recurrent forms of disease can occur. This article will mainly review immune-mediated myopathies in horses. Myositis directly caused by infection such as Clostridium spp and others will not be discussed here.
Asunto(s)
Enfermedades de los Caballos , Miositis , Animales , Enfermedades de los Caballos/inmunología , Enfermedades de los Caballos/microbiología , Caballos , Miositis/veterinaria , Miositis/inmunología , Miositis/microbiología , Enfermedades Autoinmunes/veterinaria , Enfermedades Autoinmunes/inmunologíaRESUMEN
Immunomodulators can stimulate, suppress, or regulate one or many aspects of the immune response. Use of a variety of immunostimulants, immunosuppressors, and anti-inflammatory drugs are described in horses, but the evidence supporting their efficacy is variable. Corticosteroids and nonsteroidal anti-inflammatory drugs are the best characterized immunomodulators in horses, but further study is needed to fully define their ideal dosing protocols and indications and to characterize the efficacy of other immunomodulators in equine medicine.
Asunto(s)
Enfermedades de los Caballos , Animales , Caballos , Enfermedades de los Caballos/tratamiento farmacológico , Enfermedades de los Caballos/inmunología , Agentes Inmunomoduladores/uso terapéutico , Agentes Inmunomoduladores/farmacología , Factores Inmunológicos/uso terapéutico , Factores Inmunológicos/farmacología , Enfermedades del Sistema Inmune/veterinaria , Enfermedades del Sistema Inmune/tratamiento farmacológico , Antiinflamatorios/uso terapéuticoRESUMEN
Alloimmune disorders occur in foals when pregnant mares produce antibodies against antigens on the foal's cells or tissues, and concentrate them within colostrum. Once foals nurse and absorb colostral antibodies, they can develop hematologic or cutaneous manifestations that can occur individually or in combination. These include neonatal isoerythrolysis, a hemolytic anemia directed against factors on the foal's erythrocytes, alloimmune thrombocytopenia when the antibodies are directed against platelet antigens, alloimmune neutropenia when they are directed against neutrophil antigens, and a combination of suspected alloimmune ulcerative dermatitis, neutropenia and thrombocytopenia. Foals can also develop neutrophilic dermatitis which is suspected to be alloimmune.
Asunto(s)
Animales Recién Nacidos , Enfermedades de los Caballos , Animales , Caballos , Enfermedades de los Caballos/inmunología , Animales Recién Nacidos/inmunología , Femenino , Embarazo , Calostro/inmunologíaRESUMEN
Strangles is a highly contagious disease of the equine upper respiratory tract caused by Streptococcus equi subspecies. Streptococcus equi subsp. equi (S. equi) and Streptococcus equi subsp. zooepidemicus (S. zooepidemicus) was isolated, as local, hot, and field strains, from horses clinically suffering from respiratory distress. The isolated Streptococci were identified using bacteriological and molecular techniques. Four formulations of inactivated S. equi vaccines were developed and evaluated. The first formulation was prepared using the S. equi isolates, adjuvanted with MONTANIDE GEL adjuvant, while the second formulation was adjuvanted with MONTANIDE ISA-70 adjuvant. The other 2 formulations were inactivated combined vaccines prepared from both S. equi and S. zooepidemicus isolates. The 3rd formulation was the combined isolates adjuvanted with MONTANIDE GEL while the 4th formulation was the combined isolates adjuvanted with MONTANIDE ISA-70. The developed vaccines' physical properties, purity, sterility, safety, and potency were ensured. The immunizing efficacy was determined in isogenic BALB/c mice and white New Zealand rabbits using the passive hemagglutination test. Also, the antibodies' titer of the combined S. equi and S. zooepidemicus vaccine adjuvanted with MONTANIDE ISA-70 in foals was tracked using an indirect enzyme-linked immunosorbent assay. The protective efficacy of the developed vaccines was determined using a challenge test in both laboratory and field animal models, where a 75% protection rate was achieved. The combined vaccine proved to be more efficacious than the monovalent vaccine. Also, the MONTANIDE ISA-70 adjuvant provided significant protective efficacy than the MONTANIDE GEL. The current work is introducing a very promising mitigative and strategic controlling solution for strangles.
Asunto(s)
Enfermedades de los Caballos , Ratones Endogámicos BALB C , Infecciones Estreptocócicas , Vacunas Estreptocócicas , Streptococcus equi , Streptococcus , Animales , Streptococcus equi/inmunología , Caballos , Conejos , Infecciones Estreptocócicas/veterinaria , Infecciones Estreptocócicas/prevención & control , Infecciones Estreptocócicas/microbiología , Infecciones Estreptocócicas/inmunología , Ratones , Enfermedades de los Caballos/prevención & control , Enfermedades de los Caballos/microbiología , Enfermedades de los Caballos/inmunología , Vacunas Estreptocócicas/inmunología , Vacunas Estreptocócicas/administración & dosificación , Femenino , Anticuerpos Antibacterianos/sangre , Adyuvantes Inmunológicos/administración & dosificación , Vacunas de Productos Inactivados/inmunologíaRESUMEN
During hospitalization horses may develop gastrointestinal conditions triggered by a stress-associated weak local immune system. The prospective, clinical trial was conducted to find out whether fecal immunoglobulin A (IgA) concentrations could be determined in hospitalized horses and how they changed during hospitalization and in response to various stressors. Samples were obtained from 110 horses and a control group (n = 14). At arrival in the hospital, horses were categorized into pain grades (1-5), and elective versus strenuous surgery (> 2 hours, traumatic and emergency procedures). Feces were collected on day 1, day 2, day 3, and day 7 in all horses. Blood samples were obtained at the same intervals, but additionally after general anaesthesia in horses undergoing surgery (day 2). IgA concentration in feces was determined by ELISA and measured in optical density at 450nm. The control group showed constant IgA concentrations on all days (mean value 0.30 OD450 ±SD 0.11, 1.26 mg/g; n = 11). After general anaesthesia fecal IgA concentrations decreased considerably independent of duration and type of surgery (P < 0.001 for elective and P = 0.043 for traumatic surgeries). High plasma cortisol concentrations were weakly correlated with low fecal IgA on the day after surgery (P = 0.012, day 3, correlation coefficient r = 0.113). Equine fecal IgA concentrations showed a decline associated with transport, surgery, and hospitalization in general, indicating that stress has an impact on the local intestinal immune function and may predispose horses for developing gastrointestinal diseases such as enterocolitis.
Asunto(s)
Heces , Inmunoglobulina A , Animales , Caballos , Inmunoglobulina A/metabolismo , Inmunoglobulina A/análisis , Inmunoglobulina A/sangre , Heces/química , Masculino , Femenino , Enfermedades de los Caballos/inmunología , Enfermedades de los Caballos/metabolismo , Enfermedades de los Caballos/sangre , Hospitalización/estadística & datos numéricos , Estrés Fisiológico/inmunologíaRESUMEN
Host immune analyses require specific reagents to identify cellular and soluble components of the immune system. These immune reagents are often species-specific. For horses, various immunological tools have been developed and tested by different initiatives during the past decades. This article summarizes the development of well characterized monoclonal antibodies (mAbs) for equine immune cells, immunoglobulin isotypes, cytokines, and chemokines.
Asunto(s)
Anticuerpos Monoclonales , Caballos , Técnicas Inmunológicas , Animales , Anticuerpos Monoclonales/inmunología , Quimiocinas/inmunología , Citocinas/inmunología , Enfermedades de los Caballos/inmunología , Caballos/inmunología , Isotipos de Inmunoglobulinas/inmunología , Técnicas Inmunológicas/veterinariaRESUMEN
Herpesviruses establish a well-adapted balance with their host's immune system. Despite this co-evolutionary balance, infections can lead to severe disease including neurological disorders in their natural host. In horses, equine herpesvirus 1 (EHV-1) causes respiratory disease, abortions, neonatal foal death and myeloencephalopathy (EHM) in ~10â% of acute infections worldwide. Many aspects of EHM pathogenesis and protection from EHM are still poorly understood. However, it has been shown that the incidence of EHM increases to >70â% in female horses >20 years of age. In this study we used old mares as an experimental equine EHV-1 model of EHM to identify host-specific factors contributing to EHM. Following experimental infection with the neuropathogenic strain EHV-1 Ab4, old mares and yearling horses were studied for 21 days post-infection. Nasal viral shedding and cell-associated viremia were assessed by quantitative PCR. Cytokine/chemokine responses were evaluated in nasal secretions and cerebrospinal fluid (CSF) by Luminex assay and in whole blood by quantitative real-time PCR. EHV-1-specific IgG sub-isotype responses were measured by ELISA. All young horses developed respiratory disease and a bi-phasic fever post-infection, but only 1/9 horses exhibited ataxia. In contrast, respiratory disease was absent in old mares, but all old mares developed EHM that resulted in euthanasia in 6/9 old mares. Old mares also presented significantly decreased nasal viral shedding but higher viremia coinciding with a single fever peak at the onset of viremia. According to clinical disease manifestation, horses were sorted into an EHM group (nine old horses and one young horse) and a non-EHM group (eight young horses) for assessment of host immune responses. Non-EHM horses showed an early upregulation of IFN-α (nasal secretions), IRF7/IRF9, IL-1ß, CXCL10 and TBET (blood) in addition to an IFN-γ upregulation during viremia (blood). In contrast, IFN-α levels in nasal secretions of EHM horses were low and peak levels of IRF7, IRF9, CXCL10 and TGF-ß (blood) coincided with viremia. Moreover, EHM horses showed significantly higher IL-10 levels in nasal secretions, peripheral blood mononuclear cells and CSF and higher serum IgG3/5 antibody titres compared to non-EHM horses. These results suggest that protection from EHM depends on timely induction of type 1 IFN and upregulation cytokines and chemokines that are representative of cellular immunity. In contrast, induction of regulatory or TH-2 type immunity appeared to correlate with an increased risk for EHM. It is likely that future vaccine development for protection from EHM must target shifting this 'at-risk' immunophenotype.
Asunto(s)
Citocinas , Infecciones por Herpesviridae , Herpesvirus Équido 1 , Enfermedades de los Caballos , Animales , Caballos , Herpesvirus Équido 1/inmunología , Femenino , Enfermedades de los Caballos/virología , Enfermedades de los Caballos/inmunología , Infecciones por Herpesviridae/veterinaria , Infecciones por Herpesviridae/inmunología , Infecciones por Herpesviridae/virología , Citocinas/sangre , Citocinas/inmunología , Anticuerpos Antivirales/sangre , Esparcimiento de Virus , Viremia/inmunología , Viremia/veterinaria , Inmunoglobulina G/sangreRESUMEN
Rhodococcus equi (R. equi), a gram-positive facultative intracellular pathogen, is a common cause of pneumonia in foals and represents a major cause of disease and death. The aim of the present study was to investigate the time-depended changes in White Blood Cells (WBC), basophils (Baso), neutrophils (Neu), lymphocytes (Lymf), monocytes (Mon), eosinophils (Eos), platelet (PLT) counts, fibrinogen (Fbg) concentration, interferon (IFN-α, IFN-γ) and interleukins (IL-2 and IL-10) in foals with clinical R. equi pneumonia. The main treatment was with azithromycin-rifampicin for 14 days. Blood was sampled prior to, 7 and 14 days after starting therapy. Treatment was associated with significantly decreased counts of WBC, (25.6 ± 6.7 and 14.2 ± 2,7 × 103/ml), Neu (18.6 ±6.2 and 10.7 ± 3.1 × 103/ml), Mon (1.5 ± 0.5 and 0.9 ± 0.2 × 103/ml) and Fbg (539 ± 124 and 287 ± 26 g/dl) between day 0 and day 14. IL-2 and IL-10 concentrations were significantly increased (P = 0.028, P = 0.013, respectively) after treatment, whereas IFN-α and IFN-γ concentrations were not. The diagnostic potentials of INF-α, INF-γ, IL-2 and IL-10 per se seems not very high, however, the study suggests that the activity change of selected interleukins in the course of the disease may be associated with amelioration. We concluded that patterns of serum concentration changes of INF-α, INF-γ, IL-2 and IL-10 may help in the study of the innate immune response in foals during infection and treatment of R. equi pneumonia.
Asunto(s)
Infecciones por Actinomycetales , Antibacterianos , Biomarcadores , Enfermedades de los Caballos , Rhodococcus equi , Animales , Caballos/sangre , Enfermedades de los Caballos/sangre , Enfermedades de los Caballos/tratamiento farmacológico , Enfermedades de los Caballos/microbiología , Enfermedades de los Caballos/inmunología , Infecciones por Actinomycetales/veterinaria , Infecciones por Actinomycetales/tratamiento farmacológico , Infecciones por Actinomycetales/sangre , Infecciones por Actinomycetales/inmunología , Infecciones por Actinomycetales/microbiología , Antibacterianos/uso terapéutico , Biomarcadores/sangre , Neumonía Bacteriana/tratamiento farmacológico , Neumonía Bacteriana/veterinaria , Neumonía Bacteriana/sangre , Neumonía Bacteriana/inmunología , Neumonía Bacteriana/microbiología , Azitromicina/uso terapéutico , Femenino , MasculinoRESUMEN
Theileria equi (T. equi) is an apicomplexan parasite that causes severe hemolytic anemia in equids. Presently, there is inadequate knowledge of the immune responses induced by T. equi in equid hosts impeding understanding of the host parasite relationship and development of potent vaccines for control of T. equi infections. The objective of this study was to evaluate the host-parasite dynamics between T. equi merozoites and infected horses by assessing cytokine expression during primary and secondary parasite exposure, and to determine whether the pattern of expression correlated with clinical indicators of disease. Our findings showed that the expression of pro-inflammatory cytokines was very low and inconsistent during both primary and secondary infection. There was also no correlation between the symptoms observed during primary infection and expression of the cytokines. This suggests that the symptoms might have occurred primarily due to hemolysis and likely not the undesirable effects of pro-inflammatory responses. However, IL-10 and TGF-ß1 were highly expressed in both phases of infection, and their expression was linked to antibody production but not moderation of pro-inflammatory cytokine responses.
Asunto(s)
Enfermedades de los Caballos , Interleucina-10 , Theileria , Theileriosis , Factor de Crecimiento Transformador beta1 , Animales , Caballos , Theileriosis/inmunología , Theileriosis/parasitología , Interleucina-10/metabolismo , Interleucina-10/inmunología , Theileria/inmunología , Factor de Crecimiento Transformador beta1/metabolismo , Enfermedades de los Caballos/inmunología , Enfermedades de los Caballos/parasitología , Merozoítos/inmunología , Anticuerpos Antiprotozoarios/inmunología , Formación de Anticuerpos/inmunología , Citocinas/metabolismo , Interacciones Huésped-Parásitos/inmunologíaRESUMEN
Immune-mediated vasculopathies occur secondary to infection or another noninfectious stimulus. Potential triggers include heterologous antigens including viruses, injected proteins and drugs; or auto-antigens including immunoglobulins or other endogenous proteins. Although these conditions are rare in horses, immune-mediated vasculopathies can cause considerable morbidity, with variable clinical signs depending on severity and organ system affected. Examples include purpura hemorrhagica, systemic lupus erythematosus, drug-induced vasculitis, paraneoplastic vasculitis, and idiopathic immune-mediated vasculitis. Diagnosis is presumptive or based on histopathology of skin biopsies if cutaneous signs are present. Treatment relies on removing the inciting cause, immunosuppression, and supportive care.
Asunto(s)
Enfermedades de los Caballos , Vasculitis , Animales , Enfermedades de los Caballos/inmunología , Caballos , Vasculitis/veterinariaRESUMEN
Immune-mediated ocular inflammation is a common clinical diagnosis reached for horses with keratitis and uveitis. This diagnosis is made as a diagnosis of exclusion following a thorough effort to rule out an underlying cause for the inflammation, most importantly infectious and neoplastic disease. Practically, response to ophthalmic and systemic anti-inflammatory or immunomodulatory medications is used to support a diagnosis of immune-mediated ocular inflammation; however, such medications are often contraindicated in the face of infection or neoplasia. This article will summarize our current understanding and approach to the diagnosis and management of immune-mediated keratitis and recurrent or insidious uveitis in horses.
Asunto(s)
Oftalmopatías , Enfermedades de los Caballos , Animales , Enfermedades de los Caballos/inmunología , Enfermedades de los Caballos/diagnóstico , Enfermedades de los Caballos/terapia , Caballos , Oftalmopatías/veterinaria , Oftalmopatías/diagnóstico , Oftalmopatías/inmunología , Oftalmopatías/terapia , Uveítis/veterinaria , Uveítis/diagnóstico , Uveítis/inmunología , Uveítis/tratamiento farmacológico , Queratitis/veterinaria , Queratitis/diagnóstico , Queratitis/inmunologíaRESUMEN
Autoimmune dermatopathies are not common in horses. These autoimmune diseases can be idiopathic or triggered by an antigen such as drugs, vaccines, or neoplasia. The most common one is pemphigus foliaceus, which manifests as a pustular, crusting eruption. Other more common pustular diseases should be ruled out before considering pemphigus. Vasculitis is relatively common in horses and can be triggered by a variety of antigenic stimulations. Systemic lupus and true idiopathic autoimmune vasculitis are very rare in horses. Every effort should be made to reach a final diagnosis, as the prognosis for true idiopathic autoimmune skin diseases is poor.
Asunto(s)
Enfermedades Autoinmunes , Enfermedades de los Caballos , Enfermedades de la Piel , Caballos , Animales , Enfermedades de los Caballos/diagnóstico , Enfermedades de los Caballos/inmunología , Enfermedades Autoinmunes/veterinaria , Enfermedades Autoinmunes/diagnóstico , Enfermedades de la Piel/veterinaria , Enfermedades de la Piel/diagnóstico , Pénfigo/veterinaria , Pénfigo/diagnóstico , Pénfigo/patología , Pénfigo/inmunologíaRESUMEN
Equid herpesvirus 4 (EHV-4) is a common respiratory pathogen in horses. It sporadically induces abortion or neonatal death. Although its contribution in neurological disorders is not clearly demonstrated, there is a strong suspicion of its involvement. Despite preventive treatments using vaccines against EHV-1/EHV-4, the resurgence of alpha-EHV infection still constitutes an important threat to the horse industry. Yet very few studies have been conducted on the search for antiviral molecules against EHV-4. A screening of 42 antiviral compounds was performed in vitro on equine fibroblast cells infected with the EHV-4 405/76 reference strain (VR2230). The formation of cytopathic effects was monitored by real-time cell analysis (RTCA), and the viral load was quantified by quantitative PCR. Aciclovir, the most widely used antiviral against alpha-herpesviruses in vivo, does not appear to be effective against EHV-4 in vitro. Potential antiviral activities were confirmed for eight molecules (idoxuridine, vidarabine, pritelivir, cidofovir, valganciclovir, ganciclovir, aphidicolin, and decitabine). Decitabine demonstrates the highest efficacy against EHV-4 in vitro. Transcriptomic analysis revealed the up-regulation of various genes implicated in interferon (IFN) response, suggesting that decitabine triggers the immune antiviral pathway.